Korio’s Next-Generation RTSM Platform Selected For The Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial

Korio’s Next-Generation RTSM Platform Selected For The Leukemia & Lymphoma Society’s Beat AML^® Master Clinical Trial

Doylestown, PA, May 17, 2023 – Korio, a technology-first Randomization & Trial Supply Management (RTSM) company, is pleased to announce its collaboration with The Leukemia & Lymphoma Society (LLS) on its innovative Beat AML® Master Clinical Trial.

Beat AML® is the first collaborative precision medicine clinical trial for a blood cancer, using cutting-edge genomic technology to match patients to the most promising targeted treatment for their acute myeloid leukemia (AML).

LLS selected Korio as its RTSM provider to support patient enrollment and randomization for its first randomized sub study in the trial. Within trials, sponsors, contact research organizations (CROs) and clinical trial site personnel have numerous systems to interact with while treating patients. The RTSM platform will provide a more streamlined user experience for patient enrollment and sub study randomization under a complex umbrella trial protocol. Korio’s suite of best-in-class IRT (interactive response technology) functionality is nested in a comprehensive GxP framework to produce high-quality results.

“Combining Korio’s platform with the incredible work currently in progress for Beat AML® will enhance integration across its many partners, leveraging technology to support the discovery of promising new AML therapies,” said Ryan Keane, Co-founder and CEO of Korio. “We are honored that The LLS, the global leader in creating a world without blood cancer has partnered with us to help achieve their mission.”

LLS has assembled an impressive network of Beat AML® partners, including the U.S. Food & Drug Administration (FDA), top clinical sites, multiple pharmaceutical companies, and select technology experts, who have united to find cures for AML.

“Innovative technology is critical to the success of the Beat AML® Master Clinical Trial,” said Len Rosenberg, PhD, RPh, Head of Clinical Operations at LLS. “As we continue to work towards better outcomes for patients through innovation including technology adoption, we are confident that our sites and patients will benefit greatly from Korio’s streamlined experience.”

For more information on the Beat AML® Master Clinical Trial, visit www.lls.org/beataml.